Last reviewed · How we verify
lysozyme 90 mg
Lysozyme 90 mg, marketed by Eisai Co., Ltd., holds a distinct position in its therapeutic area with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | lysozyme 90 mg |
|---|---|
| Also known as | PRT10T |
| Sponsor | Eisai Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |